RESPANA’S INNOVATIVE APPROACH
is based on a novel insight into respiratory disease processes.
Using Influenza A virus (IAV), the inventors’ research shows that viruses like IAV exploit a specific receptor on lung interstitial macrophages called SP-R210.
SP-R210 is the receptor for surfactant protein A (SP-A), an essential part of the innate immune system. “Hijacking” the receptor for SP-A triggers an inflammatory response and interferes with the body’s ability to fight off the infection.
The result: prolonged inflammation, structural damage and invasion of opportunistic pathogens in the infected lung.
Respana’s goal is to develop a therapy which reduces the morbidity and mortality associated with viral infections of the lung.
Respana’s monoclonal antibody have therapeutic potential for those suffering from acute respiratory conditions like influenza, COVID-19, and subsequent infections, whether viral or bacterial.
- Curb development of Acute Respiratory Distress Syndrome (ARDS)
- Reverse lung damage by attenuating the destructive program that leads to cell death
- Promote cell survival, normal lung remodeling, and immune vigilance
- Initial Indication: Influenza-related Hospitalization and Mortality
- Initial Target Patient Population: High-Risk and Elderly
- Additional Opportunities: Emerging Viruses (e.g.; COVID-19, SARS, MERS), Chronic Lung Conditions
Promotes Natural Recovery
Respana’s therapeutic mAbs target the SP-R210 receptor, arrest development of influenza pneumonitis and preserve the body’s natural immune functioning, thereby facilitating recovery from viral infection.
Since the SP-R210 receptor likely represents a universal infectivity point for virus invasion, Respana’s monoclonal antibody should remain effective even in the presence of novel viral strains, whether seasonal or pandemic, and should not drive viral resistance.